| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
9,704 |
6,604 |
$225K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
5,013 |
3,687 |
$141K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
325 |
267 |
$10K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
239 |
207 |
$8K |
| 99490 |
Ccm add 20min |
2,398 |
2,396 |
$5K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
90 |
88 |
$4K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
276 |
140 |
$3K |
| 87428 |
|
60 |
51 |
$3K |
| 94760 |
|
6,115 |
4,963 |
$2K |
| 86403 |
|
112 |
102 |
$908.85 |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
63 |
54 |
$858.63 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
82 |
73 |
$703.40 |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
16 |
15 |
$675.00 |
| 81003 |
|
24 |
24 |
$38.07 |
| 99051 |
|
2,686 |
2,206 |
$7.00 |
| G0439 |
Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit |
31 |
29 |
$0.00 |